Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474193 | 0.94 | TSHR (0.43) | TSHRLMNAPTGS2MAPK1CYP2C9 | |
| SCHEMBL1474192 | 0.94 | TSHR (0.43) | TSHRLMNAPTGS2MAPK1CYP2C9 | |
| SCHEMBL17995472 | 0.87 | TSHR (0.43) | TSHRLMNAMAPK1CYP2C9CA1 | |
| SCHEMBL17995479 | 0.77 | TSHR (0.41) | TSHRLMNAMAPK1CYP2C9MAPT | |
| SCHEMBL12203799 | 0.72 | MAPK1 (0.49) | TSHRLMNAMAPK1CYP2C9MAPT | |
| SCHEMBL17995484 | 0.72 | TSHR (0.47) | TSHRLMNAMAPK1CYP2C9MAPT | |
| SCHEMBL16797125 | 0.72 | TSHR (0.40) | TSHRLMNAMAPK1CYP2C9MAPT | |
| SCHEMBL10910306 | 0.69 | PTAFR (0.33) | TSHRLMNACA1CA9MAPT | |
| SCHEMBL821890 | 0.68 | TSHR (0.31) | TSHRLMNAMAPK1CYP2C9 | |
| SCHEMBL9258191 | 0.68 | LMNA (0.34) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE44734-E1 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-7319154-B2 | Oxidation of 17 alpha -(3-hydroxypropyl)-6 beta ,7 beta ;15 beta ,16 beta -dimethylene-androstane-3 beta ,5 beta ,17 beta -triol in the presence of a catalytic amounts of a 2,2,6,6-tetramethylpiperidine-N-oxide derivative at a pH of at least 8.0 | BAYER SCHERING PHARMA AG (DE) | 2008-01-15 | — | — | US | disclosed |
| US-20070021603-A1 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021603-A1 | Process for the production of 3-oxo-pregn-4-ene-21,17-carbolactones by the metal free oxidation of 17-(3-hydroxypropyl)-3,17-dihydroxyandrostanes | HSD17B7, HSD17B13, HSD17B3 | TSHR 4505/4885LMNA 2506/4885PTGS2 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.